Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Journal:

The Lancet Diabetes & Endocrinology

Published:

2025-06-22

DOI:

10.1016/s2213-8587(25)00141-x

Affiliations:

25

Authors:

29

Go to article

Institutions	Authors	Share
Sciwind Biosciences Co., Ltd., China	6.000000	0.21
Peking University People's Hospital, PKUHSC, China	2.000000	0.07
The Second People's Hospital of Lianyungang, China	1.000000	0.03
Affiliated Hospital of SDMPU, China	1.000000	0.03
Pingxiang People's Hospital, China	1.000000	0.03
Second Affiliated Hospital, ZZU, China	1.000000	0.03
The First Affiliated Hospital of Soochow University, China	1.000000	0.03
Jinan Central Hospital, China	1.000000	0.03
The First Affiliated Hospital of Henan University of Science and Technology, China	1.000000	0.03
Tonghua Central Hospital, China	1.000000	0.03
People’s Hospital of Liaoning Province, China	1.000000	0.03
Xi’an Daxing Hospital, China	1.000000	0.03
CNPC Central Hospital, China	1.000000	0.03
Xianyang Hospital of Yan'an University, China	1.000000	0.03
Luoyang Third People's Hospital, China	1.000000	0.03
Handan First Hospital, China	1.000000	0.03
Beijing Friendship Hospital, Capital Medical University, China	1.000000	0.03
Second Affiliated Hospital of Nanjing Medical University, China	1.000000	0.03
The Affiliated Jiangning Hospital, Nanjing Medical University, China	1.000000	0.03
The First Affiliated Hospital of Xinxiang Medical University, China	1.000000	0.03
Xuancheng People's Hospital, China	1.000000	0.03
Shengjing Hospital of China Medical University, China	1.000000	0.03
The Second People's Hospital of Huai'an, China	1.000000	0.03

Interested in Nutrition and Dietetics?